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2005-2011 for new drugs and new indications for existing drugs were identified 
from the European Medicines Agency (EMA) website. The decision to undertake an 
appraisal was obtained from the NICE website and NIHR Horizon Scanning Centre 
records, and the associations between this and characteristics of the drug and 
intended patient population were then determined. Results: For 2005-2011, we 
identified 134 MAs granted by the EMA (116 new drugs and 18 new indications) of 
which 72 (54%) were selected for appraisal. The decision to undertake an appraisal 
was significantly associated with an MA granted 2009-2011 (OR= 2.3, p< 0.01), the 
drug being a biological agent (OR= 3.9, p< 0.01), administered on a long-term basis 
(OR= 1.8, p< 0.05), indicated for a patient population < 1 in 1,000 (OR= 2.1, p< 0.05), or 
for malignant disease (OR= 5.1, p< 0.01). It was not associated with an indication for 
more severe disease (OR= 2.0, p= 0.06), an MA issued for a new indication (OR= 1.4, 
p= 0.50), or whether a drug was first-of-kind (OR= 1.8, p= 0.10). ConClusions: We 
identified several characteristics associated with the decision to undertake an 
appraisal relating to both the drug and intended patient population that do not 
completely match published topic selection criteria (e.g. severity). Further analyses 
are required to determine which are the most relevant factors in this decision.
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Determination of Cost-effeCtiveness tHresHolD for malaysia
Lim Y.W., Shafie A.A., Chua G.N., Hassali M.A.A.
Universiti Sains Malaysia, Penang, Malaysia
objeCtives: Decision on the cost-effectiveness (CE) of health care technologies 
usually creates an argument especially when alternatives are more expensive but 
more effective. In this situation, external criterion in the form of CE threshold or 
willingness-to-pay for a quality-adjusted life-year (WTP/QALY) needs to be applied 
to decide on its CE. Nevertheless, the lack of empirical and well-accepted CE thresh-
old in Malaysia is recognized as one of the most important barriers in using health 
technology assessment for decision making. This study was mainly done to deter-
mine the CE threshold value across Malaysian population, estimated in terms of 
societal WTP for a QALY. Methods: A cross-sectional, contingent valuation study 
was conducted using stratified multistage cluster random sampling technique in the 
states of Penang, Kedah, Selangor and Kuala Lumpur Federal Territory. Respondents 
were asked for the socioeconomic background, quality of life and their WTP for a 
hypothetical EQ-5D health state scenario (treatment, extended life in terminal ill-
ness and life saving situations with three health severities – mild, moderate and 
severe, and two QALY gained levels – 0.2 QALY and 0.4 QALY) using pre-designed 
questionnaires. Interval model analysis was applied to determine the CE thresh-
old. Results: One thousand thirteen respondents aged between 20–60 years old 
who can understand either English or Malay language were interviewed face-to-
face. The mean value of CE threshold was determined at the range of MYR 19,929 to 
MYR 28,469 (~ USD 6,200 to USD 8,900). ConClusions: By comparing our results to 
Malaysian GDP per capita in the year 2013; ~ MYR 33,754 (~ USD 10,548), we noted 
that the mean WTP/QALY is ranged between 0.59–0.84 times of GDP per capita.
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systematiC review of eConomiC evaluation of HealtH teCHnologies 
DeveloPeD in Brazil from 1980-2013
Decimoni T.C.1, Leandro R.1, Soarez P.1, Craig D.2
1Sao Paulo University, São Paulo, Brazil, 2University of York, York, Brazil
objeCtives: The aim of this study is to review published economic evaluation of 
health technologies conducted in Brazil. Methods: Systematic review of economic 
evaluations studies published in MEDLINE, EMBASE, LILACS, SciELO, NHS EED, HTA 
Database, Web of Science, SCOPUS, BVS ECOS and SISREBRATS from 1980 to 2013. 
Full (Cost consequence analysis - CCA, cost minimization analysis - CMA, cost-
effectiveness analysis - CEA, cost-utility analysis - CUA, and cost-benefit analysis 
- CBA) and partial (cost description - CD and cost analysis - CA) economic evalua-
tion studies were eligible for inclusion if at least one of the authors was Brazilian 
and was affiliated to a Brazilian institution. Two independent reviewers screened 
articles for relevance and carried out data extraction. Disagreements were resolved 
through discussion or through consultation with a third reviewer. We performed a 
qualitative narrative synthesis. Results: We identified 11946 records and 557 met 
inclusion criteria. One hundred and ninety (34.1%) were full (of these, 56.6% CEA, 
20.3% CCA, 12.7% CUA, 5.6% CMA, and 4.7% CBA), and 367 were partial economic 
evaluation (of these, 64.7% CD and 32.3% CA). The main health problem studied were 
Infectious and Parasitic diseases (17.1%), Diseases of the Circulatory System (12.3%) 
and Neoplams (10.3%). The majority (72.9%) was conducted by authors from the 
southeast region, and south region (12.6%), mainly linked to academia (69.5%), and 
54.2% were published in medical and 18.9% in public health journals. Seventy-two 
(14.7%) studies reported to be funded by industry and 16% was considered to have 
conﬂict of interest. ConClusions: There was a considerable growth in the conduct 
and publication of economic evaluation studies in Brazil. A qualitative evaluation 
of the methodology used in those studies is important to legitimize their use in the 
process of local decision-making.
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a literature review of Patient aDvoCaCy grouP (Pag) involvement 
in Hta
Hicks N.1, Hawken N.A.2, Arvin-berod C.1, Toumi M.3
1Commutateur, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3University Aix-
Marseille, Marseille, France
objeCtives: Patient input is an important part of the assessment process, yet some-
times seen as having a low evidence base. Previous work by the authors shows more 
research is needed on identifying how the patient group contribution is impacting 
decision making. Our objective was to review and critically appraise existing pub-
lications on PAG involvement in HTA. Methods: A search in Pubmed, Cochrane 
and ISPOR databases since 2009 was undertaken to identify studies on patients 
or PAG involvement in the HTA decision. Studies were evaluated for relevancy. 
We extracted information on perceptions of patient input, process improvement 
recommendations, comparison of patient pathways and specific type of patient 
input desired. Two reviewers extracted methodological details, study designs, and 
outcomes into summary tables. Results: We identified 21 articles out of a total of 
18,829 studies. Articles covered multiple subject areas. Process improvements were 
most common (4 studies) followed by current perceptions (3 studies), comparison 
of patient pathways (2 studies) and specific type of patient input desired (1 study). 
Research methodologies and stakeholders varied widely including telephone, web 
audit, interview /questionnaire and literature review. Stakeholders varied between 
national & international HTA agencies, experts and patient groups. Three studies 
involved patient groups and one involved patients. These studies informed the role, 
process and nature of input but did not address the impact on HTA decision mak-
ing. ConClusions: Compared to other HTA areas there is a lack of published mate-
rial on PAG involvement. There have been many attempts to provide a framework 
for patient involvement but so far none has been used in HTA decision-making. 
Existing data does not help to quantify role of the patient in HTA decision making. 
Additional research is needed to understand and quantify patient group input in 
HTA decisions.
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trenDs anD Key DeCision Drivers for rejeCting an orPHan Drug 
suBmission aCross five Different Hta agenCies
Mardiguian S., Stefanidou M., Sheppard F.
PAREXEL, London, UK
objeCtives: Access to orphan drugs is often inconsistent, and is hindered by dif-
ficulties in demonstrating value in HTA appraisals due to the small patient popula-
tions and insufficient data. To inform future submissions, we examined the trends 
and key decision drivers that resulted in a submission being rejected across five HTA 
agencies. Methods:  The Orphanet database was searched for orphan drugs with a 
marketing authorisation between 2002 and 2014. To assume a certain level of com-
petition, awareness and commercial potential, rare diseases for which two or more 
orphan drugs were available were selected. Decisions from five HTA agencies were 
considered: AWMSG (Wales), CADTH (Canada), NICE (England), PBAC (Australia), 
and SMC (Scotland). Assessments that resulted in a rejection were examined for 
key decision drivers, and for trends and variation by disease type. Results: A total 
of 28 licensed orphan drugs were available for the treatment of eight rare diseases. 
The number of orphan drugs assessed, and rejection rates, varied by HTA agency; 
PBAC and SMC had the lowest rejection rates (4/18; 22% and 6/22; 27%, respectively), 
while NICE had the highest rejection rate with 40% (4/10). Uncertainties regarding 
clinical efficacy, and concerns over the robustness of economic evidence were the 
key decision drivers that led to a rejection. Examination of data by disease type 
indicated a trend towards higher rejection rates for diseases with a higher preva-
lence rate. ConClusions: The proportion of rejected submissions varied by HTA 
agency, particularly within the HTA bodies in the UK, highlighting inconsistencies 
in decision-making. An association between prevalence rate and the proportion of 
rejected submissions was found, with lower rates of disease prevalence correlating 
with higher acceptance rates. This is most likely due to the lower budget impact 
incurred in smaller patient populations.
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PreDiCtors of german amnog DeCisions anD gKv reBate 
negotiations: a DataBase analysis
Verleger K.1, Schoeman O.1, Schmidt R.1, Wilke T.2, Heeg B.1
1Pharmerit International, Berlin, Germany, 2IPAM - Institute for Pharmacoeconomics and 
Medication Logistics, Wismar, Germany
objeCtives: G-BA, IQWiG and GKV are the main governmental stakeholders in 
the German AMNOG process. Based on manufacturer-submitted dossiers, the G-BA 
assesses the drugs’ additional benefit per pre-defined subgroup. Subsequently, the 
GKV negotiates rebates by drug. This research aims to describe factors influenc-
ing GB-A decisions and assess the association between additional benefit and 
rebate. Methods: All G-BA decisions up to March 2014 were analyzed. Univariate 
logistic regression was used to investigate the relationship of G-BA decisions 
(dependent variable: additional benefit (y/n) per subgroup) with study character-
istics. Study characteristics included were disease area (ATC-code), superiority/
non-inferiority study design, comparators used in the submitted trials (in/direct; 
in/adequate comparator according to GBA [“ZVT”]), main area of claimed benefit 
e.g. overall survival (OS). Linear regression was used to assess the impact of added 
benefit (in at least one subgroup) on rebate. Results: Sixty-eight G-BA decisions, 
with in total 137 G-BA subgroups, were included and analyzed. In total, 60.3% of 
assessments resulted in an additional benefit. Most commonly, dossiers were sub-
mitted to the G-BA for ATC-codes L and A (39.7%; 19.1%). Out of 40 ATC-code L sub-
groups (27 drugs), 70.0% resulted in a positive assessment, with 50% demonstrating 
a benefit in OS. Univariate logistic regression showed a significant relationship 
between added benefit and: ATC-codes A/J/L; improvements in morbidity; adverse 
events; direct comparators; and the ZVT (ORs: 0.1; 11.2; 6.0; 55.2; 24.3; 20.9; 15.2; all 
p< 0.05). All drugs showing an OS advantage received a positive benefit assessment. 
Added benefit reduced the rebate significantly by 13.1% (p< 0.05). ConClusions: 
Key factors for a positive G-BA benefit assessment are improved OS, morbidity, and 
adverse events, demonstrated through the use of direct “ZVT” comparators. ATC-
codes J and L carry the highest chance of gaining a positive assessment. The rebate 
negotiated with the GKV decreases significantly if an added benefit is determined.
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niCe restriCtiveness ComPareD to tHe marKet autHorization
Jaksa A, Westbrook L., Rubinstein E., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
objeCtives: To determine how often NICE recommendations are more restrictive 
than the market authorizations. Methods: 161 NICE Technology Appraisal deci-
sions from 2007-2013 were evaluated. These reviews included 80 unique drugs from 
37 disease conditions. For each generic drug included in a review, the corresponding 
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market authorization was retrieved from the EMA or MHRA. NICE positive decisions 
were compared to the market authorizations. Any decision that included language 
that restricted the population eligible for reimbursement for a given therapy was 
categorized as “recommend with restrictions.” NICE positive decisions that were not 
more restrictive than the market authorization were categorized as “recommend.” 
Negative decisions were categorized as “do not recommend.” Restrictions were also 
quantified and categorized. Results: NICE issued “do not recommend” decisions 
in 32% of the reviews from 2007-2013. The overall rate at which NICE issued “do not 
recommend” decisions increased after 2010, but this did not pass traditional levels of 
statistical significance (p= .21). NICE issued positive decisions in 68% of reviews, but 
the decision was more restrictive than the market authorization in 52% of the posi-
tive decisions. NICE’s restrictiveness has decreased since 2007, with the exception 
of 2013 where 60% of NICE’s positive decisions were “recommend with restrictions.” 
For the “recommend with restrictions” reviews, there are 1.7 restrictions on average 
(range 1-4, s.d. 11) added to the market authorization. The most prevalent type of 
restrictions were for contraindicated or intolerance.” ConClusions: In 2007-2013, 
NICE issued “recommend with restrictions” decisions in 36% of reviews and issued 
both “recommend” and “do not recommend” decisions in 32% of reviews. NICE was 
more restrictive than the market authorization in 52% of the positive decisions, 
though NICE’s restrictiveness seems to be declining over time. An independent 
analysis of NICE decisions in 2007-2013 found a statistically significant different 
distribution of decisions than reported in the NICE website (p= .01).
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multiCriteria DeCision analysis (mCDa) in Hta – Pilot stuDy in tHe 
CzeCH rePuBliC
Hajek P.1, Pecen L.2, Bulejova L.3, Cook M.4, Dolezal T.5, Dolezel J.6, Duba J.7, Dukova I.8, Fuksa 
L.9, Heislerova M.10, Jaskova K.8, Karasek P.11, Klimes J.12, Kminek A.13, Kucera Z.14, Vesela Š.15, 
Vothova P.1, Svihovec J.10
1Pfizer s.r.o., Prague, Czech Republic, 2CEEOR s.r.o., Prague, Czech Republic, 3InterMune, 
Muttenz, Switzerland, 4BAYER s.r.o., Prague, Czech Republic, 5VALUE OUTCOMES, Prague, 
Czech Republic, 6GlaxoSmithKline, s.r.o., Prague, Czech Republic, 7OAKS Consulting s.r.o., Prague 
9, Czech Republic, 8Merck, Prague, Czech Republic, 9General Health Insurance Company of the 
Czech Republic, Praha, Czech Republic, 10University Hospital in Motol, Prague, Czech Republic, 
11Novartis s.r.o., Prague, Czech Republic, 12iHETA, Prague, Czech Republic, 13AstraZeneca, Prague, 
Czech Republic, 14Sanofi-Aventis, Prague, Czech Republic, 15Janssen, Prague, Czech Republic
objeCtives: Multicriteria Decision Analysis (MCDA) is an analytical quantitative 
instrument focused on supporting the decision-making process between alternative 
products based on multiple criteria. Methods: In the pilot study on MCDA applica-
tion in HTA in the Czech Republic, the following criteria were chosen by the experts: 
efficacy/effectiveness, safety, budget impact, disease severity, cost effectiveness 
and unmet needs. The number of evaluators was 10. Each evaluator determined 
weights within the range from 1 to 10 (from the least to the most important). The 
resultant weights were displayed as an arithmetic mean of weights of the indi-
vidual evaluators and as a trimmed mean with the minimum and maximum values 
discarded. The weights were also calculated by discarding the last evaluator, i.e. 
there were 4 sets of weights examined, each time normalized by 100%. Results: 
Each evaluator rated 5 chosen medicines with weights 0, 1, 2, 3 within the chosen 
categories. Afterwards, the mean scores and trimmed means with the lowest and 
the highest values discarded were determined for each of the 5 medicinal products 
chosen. All 8 estimates (4 weights times 2 mean scores) lead to the identical clas-
sification of medicinal products which proves the robustness of the approach. The 
biggest divergences between the evaluators‘ assessment of the same medicinal 
product was observed in case of its safety, whereas the slightest were considered 
the budget impact and cost-effectiveness. On the other hand, the differences in 
the cost-effectiveness assessment of the 5 medicinal products considered were 
followed by the greatest discrepancies as regards the budget impact. The MCDA s 
was compared with the classifications of the medicinal products based on the ICER 
only which revealed significant differences (e.g., 2nd place according to the ICER 
vs. 5th according to the MCDA). ConClusions: The MCDA brings new information 
with respect to the each criterion‘s separate application.
PHP208
out witH tHe olD – in witH tHe new: woulD new soCial PreferenCe 
weigHts for eq-5D inevitaBly require a reaPPraisal of Previous Cost-
effeCtiveness Determinations?
Kind P., Meads D.M.
University of Leeds, Leeds, UK
objeCtives: Social preferences are widely used in economic evaluation required by 
regulatory agencies. In the UK, NICE requires the use of EQ-5D and its associated set 
of TTO preference weights for computing QALYs. The weights in question date back 
nearly two decades. It is reasonable to question whether they continue to represent 
contemporary social preferences. Were a revised set of EQ-5D weights to be pro-
duced then would this necessitate the revision of all past appraisal decisions? This 
paper presents the 1stphase of work designed to address that question. Methods: 
The ICER is defined by the ratio of marginal cost (Δ C) /marginal benefit (Δ B). For a 
given Δ C the ICER falls as Δ B increases. For a given threshold (λ ) and for a fixed incre-
mental cost (Δ C), there is a minimum health benefit Δ Bmin (given by Δ C/λ ) which 
must be achieved to produce an ICER that comes below that threshold limit. TTO-
weighted scores were computed for all 243 health states defined by the 3-level ver-
sion of EQ-5D. A difference matrix was created in which D(i,j) contains the numeric 
difference between the ith and jth state. The number of differences below a given 
Δ Bmin was computed for each column (health state). Threshold values were varied 
(£20,000-£50,000). Cost differences were varied (£500-£10,000). Results: Less than 
10% of health state value differences failed to meet the minimum Δ Bmin of 0.0125 
(Δ C = £500; λ = £20,000) indicating susceptability to changes in health state value, 
however this proportion rose to 57% for higher incremental costs (e.g. Δ C = £3,000). 
81/243 health states account for 50% of the differences that exceed Δ Bminat all 
tested levels of Δ C and λ . Graphical representation of these Results can be used 
to assess the need for reappraisal. ConClusions: For higher cost interventions, 
relatively small differences in EQ-5D weights can generate ICERs with the propensity 
to reverse previous cost-effectiveness decisions.
PHP209
DeCision Drivers for Brazil: an analysis of ConiteC 
reCommenDations
Kreeftmeijer J.1, Skaltsa K.2, Palazzolo D.3
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Barcelona, Spain, 
3Quintiles Consulting, Reading, UK
objeCtives: Since its establishment in December 2011, Brazil’s HTA body CONITEC 
(National Commission on the Incorporation of Technologies), has published more 
than 90 assessments. The objective of the present study was to perform an analysis 
on CONITEC’s positive and negative decisions, in order to understand the main deci-
sion drivers. Methods: All assessments published by CONITEC between December 
2001 and April 2014 were included in our analysis. The rationale for the decisions 
was analyzed for both positive and negative recommendations. Reasons for recom-
mending or rejecting a technology were summarized into categories. Results: In 
total, 101 publications were identified: 67 of those assessed drugs, 12 a procedure or 
intervention and 11 a medical device. The remaining 11 were clinical guidelines (not 
included in the analysis). Overall, 46 recommendations were positive and 44 nega-
tive. The main reasons for rejection were concerns about the economic evidence 
(23 reports) or lack to demonstrate significant additional clinical benefits (22). The 
main reasons for positive recommendations were demonstrated clinical efficacy 
benefit (21), low budget impact (19) and fulfillment of high unmet needs (15). In 
the majority of cases, the decision was based on multiple factors. ConClusions: 
Brazil has set the way for a more transparent process for technology assessment 
following a formal process including pharmacoeconomic guidelines. However, insuf-
ficient clinical benefits and methodological concerns about the economic evalua-
tion as major rejection drivers reveals that manufacturers are not yet addressing 
CONITEC’s requirements. Full transparency on the evaluation of outcomes is still 
missing, providing additional complexity for manufacturers towards a positive rec-
ommendation. Our results demonstrated a positive relation between acceptance 
and demonstrated clinical efficacy, as well as a low budget impact. CONITEC seems 
to follow a specific pathway in their decision that should be leveraged by manufac-
turers in order to increase their likelihood of receiving a positive recommendation.
PHP210
tHe risKy Business of Drug DeveloPment: tHe final say of national 
Hta agenCies on a PHarmaCeutiCal’s Benefit During tHe last 
stretCH of an exPensive, long-lasting anD arDuous DeveloPment 
journey – as illustrateD By tHe DeCisions of germany’s gemeinsamer 
BunDesaussCHuss (g-Ba)
Maetzel A.1, Staab T.R.2, Ruof J.2
1Berlikon LLC, Chapel Hill, NC, USA, 2Roche Pharma, Grenzach-Wyhlen, Germany
objeCtives: Since 2011 Germany follows a formal process of evaluating new phar-
maceuticals for their incremental benefit vs. an appropriate comparator to inform 
price negotiations with Insurers. This study summarizes the rationale underlying 
the German authorities’ (G-BA) final assessment of manufacturers’ submissions 
following successful approval by regulators. Methods: G-BA decisions (1/2011 to 
2/2014) were evaluated for their alignment (full, partial or none) between manu-
facturer’s development programs and expectations concerning: (1) target popula-
tion; (2) comparator; (3) clinical endpoints, including indirect comparisons. Also 
addressed was the role of safety and how the G-BA addressed the potential for 
bias. Results: Of 69 completed submissions, 3 were resubmissions and 7 lacked 
a dossier. 59 completed submissions were subjected to a detailed review. Ten (17%) 
were for orphan disease indications. Major disagreement existed for 37 (63%), of 
which 17 (46%) were considered fully inadequate, and 20 (54%) inadequate for sig-
nificant subgroups. Main reasons for inadequacy were: wrong comparator (27 of 37 
[73%], wrong endpoint 6 [16%] and use of historical controls (3 [11%]). For 34 (92%) 
the major disagreement also led to a lower benefit judgment. All 19 indirect treat-
ment comparisons were considered flawed. Safety was a differentiator for 24 of the 
59 submissions, either primary (2) or in addition to efficacy (22). G-BA disagreed 
with the manufacturer on safety for 12 (50%) of the 24 submissions. ConClusions: 
This analysis of the first 3 years of G-BA’s early benefit appraisal illustrates that a 
majority of the submissions fail to convince the German authorities despite having 
obtained licensing approval. A wrong comparator was the main reason for full or 
partial rejection. Indirect treatment comparisons were never accepted. Decisions 
taken early in the development program have important repercussions on reim-
bursement negotiations with authorities in Germany.
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Hta ePiDemiology Data in Different geograPHiCal regions: 
investigation of requirements for onCology Drugs
Chadda S., Chandler T.
PHMR Associates, Newcastle upon Tyne, UK
objeCtives: Harmonisation of health technology assessment (HTA) processes 
between countries is a logical and efficient solution to complex data gathering 
exercises required of pharmaceutical manufacturers when preparing submissions. 
However, harmonisation is a slow process and potentially substantial differences 
between countries exist. Further, some types of data will inevitably need to be 
country-specific to meet local HTA requirements. Epidemiological data can be 
considered one such source of information. Methods: We reviewed HTA require-
ments in Australia, England and Wales, Japan and Scotland for epidemiology data 
requirements in their submission. Specific data types were identified and compared 
across the geographical regions. Results: Clear requirements were available for 
Australia (Pharmaceutical Benefits Advisory Committee [PBAC]), England and Wales 
(National Institute for Health and Care Excellence [NICE]), and Scotland (Scottish 
Medicines Consortium [SMC]). As of April 2014, there is an ongoing development 
